T-cell responses to highly conserved SARS-CoV-2 epitopes in Hispanic Americans receiving an mRNA COVID-19 vaccine

by Elena Iemma | May 28, 2025

Identification of immunodominant T cell epitopes induced by natural Zika virus infection

by Elena Iemma | Aug 30, 2023

In silico immunogenicity assessment for sequences containing unnatural amino acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements

by Elena Iemma | Oct 11, 2022

Predicting Immunogenicity of Peptide Drugs and Their Impurities Using in Silico Tools: Taspoglutide Case Study

by Annie De Groot | May 15, 2019

EpiVax_TaspoglutidePoster_14May19

Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics…of Peptides and P-ANDAS

by Annie De Groot | Oct 30, 2018

EpiVax_EuroTIDES_PANDA_02Nov18 To learn more about EpiVax’s PANDA Program, read our latest entries. PANDA screening Interview with Brian Roberts: Protein Therapeutics Manager PANDA Press Release